To meet a U.S. goal to effectively treat and prevent Alzheimer’s disease by 2025, patient, caregiver, and advocacy communities are recommending a $289 million hike in federal research dollars for fiscal year 2022. UsAgainstAlzheimer’s is supporting that recommendation — and calling for greater urgency in meeting national Alzheimer’s…
A virtual celebrity-studded HFC event aimed at caregivers for Alzheimer’s disease and dementia patients is on tap for Friday, National Caregivers Day. Called HFC CareCon and presented by Kensington Senior Living in both English and Spanish, the free two-hour event will be hosted by HFC co-founder and actor…
Simufilam, an investigational oral medication being developed by Cassava Sciences, improved cognition and behavior in people with Alzheimer’s disease after six months of dosing in a clinical trial, interim data show. “Today’s data once again suggests simufilam could be a transformative, novel therapeutic,” Nadav Friedmann, MD, PhD, chief medical…
Older Blacks in the U.S. are twice as likely to develop Alzheimer’s disease (AD) as whites of a similar age, and they’re less likely to be diagnosed. Such a health disparity is why the Alzheimer’s Association is presenting a webinar on Feb. 18, marking Black History Month. Called…
Note: This story was updated Feb. 9, 2021, to clarify details surrounding the grant Chronic Care Collaborative received from Adira. Greg Smiley’s world changed abruptly in 2013. He was racing down a mountain road on an outback cycling trip in South Africa, when he hit an obstruction in the road…
NeurMedix has announced it will soon open a pivotal Phase 3 clinical trial of its lead investigational therapy, NE3107, for people with Alzheimer’s disease, following authorization by the U.S. Food and Drug Administration (FDA). The trial (NCT04669028), to be conducted at about 30 clinical U.S. sites, will be looking to…
Troriluzole, an investigational oral symptomatic treatment developed by Biohaven for Alzheimer’s disease, did not work better than a placebo in alleviating cognitive impairments and reducing brain volume loss in patients with mild-to-moderate disease, according to top-line data from a Phase 2/3 trial. However, a subgroup analysis — performed…
The U.S. Food and Drug Administration (FDA) has extended its review period for aducanumab (BIIB037), an investigational therapy for Alzheimer’s disease being co-developed by Biogen and Eisai. The three-month extension means the new deadline to review the compound’s biologics license application (BLA), also known as the Prescription…
People with Alzheimer’s disease, as well as their caregivers, are being urged — on social media and via press releases — to get COVID-19 vaccines as soon as possible. That’s the recommendation of the Medical, Scientific and Memory Screening Advisory Board of the Alzheimer’s Foundation of America (AFA). “Getting…
Cognito Therapeutic’s neurostimulation device — a next-generation digital therapeutic designed to treat memory and cognition symptoms in Alzheimer’s disease — has been granted a breakthrough device designation by the U.S. Food and Drug Administration (FDA). The device, part of a new class of disease-modifying digital therapies, uses proprietary,…
Get regular updates to your inbox.